Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05491733 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of APX001 High-load and Low-load Tablets
A Phase 1 study of Invasive Fungal Infections, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05491733 is a Phase 1 study of Invasive Fungal Infections that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 18 participants, below the 48-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05491733, a Phase 1 study of Invasive Fungal Infections, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
Conditions Studied
Interventions
- DRUG APX001
- DRUG APX001A
Study Locations (1)
Utah
- Pharmaceuticals Research Associates, Inc - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2021-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05491733
The ClinicalTrials.gov registry entry for NCT05491733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target (62% lower). The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Invasive Fungal Infections appearing as the primary indexed condition, and to 2 interventions - of which APX001 is the first listed.
NCT05491733 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05491733 about?
NCT05491733 is a clinical study titled "A Bioequivalence Study of APX001 High-load and Low-load Tablets". A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
What is the current status of trial NCT05491733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-03-02. Estimated completion is 2021-06-23.
What conditions does trial NCT05491733 study?
This clinical trial studies the following conditions: Invasive Fungal Infections.
What interventions are being tested in trial NCT05491733?
The interventions under investigation include: APX001 (DRUG), APX001A (DRUG).
Who is sponsoring clinical trial NCT05491733?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05491733 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Fungal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
COMPLETED
-
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
COMPLETED
-
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
COMPLETED · Phase 3
-
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.